TransMedics Group, Inc. (NASDAQ:TMDX) Stock Holdings Decreased by Van ECK Associates Corp

Van ECK Associates Corp lowered its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 16.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 987 shares of the company’s stock after selling 192 shares during the period. Van ECK Associates Corp’s holdings in TransMedics Group were worth $155,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Harbor Capital Advisors Inc. increased its position in shares of TransMedics Group by 48.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,964 shares of the company’s stock worth $1,407,000 after purchasing an additional 2,916 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the last quarter. New York State Teachers Retirement System bought a new stake in shares of TransMedics Group during the 3rd quarter valued at about $1,217,000. State of Alaska Department of Revenue bought a new stake in shares of TransMedics Group during the 3rd quarter valued at about $2,560,000. Finally, Louisiana State Employees Retirement System bought a new stake in shares of TransMedics Group during the 3rd quarter valued at about $2,528,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Up 1.4 %

Shares of NASDAQ TMDX opened at $92.73 on Thursday. The stock has a market cap of $3.11 billion, a P/E ratio of 103.60 and a beta of 2.08. The firm has a 50 day moving average price of $129.09 and a 200 day moving average price of $139.89. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 52-week low of $61.98 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.12) EPS. Analysts expect that TransMedics Group, Inc. will post 1.07 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TMDX has been the subject of a number of recent research reports. Robert W. Baird lowered their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Oppenheimer reduced their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Stephens upped their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Needham & Company LLC cut their target price on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group presently has a consensus rating of “Buy” and a consensus target price of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.